{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "adds_modification",
    "modifications" : [ {
      "modification_type" : "methylation"
    } ],
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P42771",
      "entity_text" : "CDKN2A",
      "entity_type" : "protein"
    },
    "is_direct" : false,
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0700" ],
      "Organ" : [ "uberon:UBERON:0000105" ]
    }
  },
  "verbose_text" : "CDKN2A hypermethylation, which is frequent in patients with ESCC, accounts for 40-62% of cases, however, there is lack of valid evidence to confirm methylated CDKN2A as a biomarker for ESCC.",
  "reading_complete" : "2020-08-02T14:21:45Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T14:20:23Z",
  "trigger" : "hypermethylation",
  "evidence" : [ "CDKN2A hypermethylation" ],
  "pmc_id" : "6657975",
  "score" : 0
}